UK medical cannabis cultivator Glass Pharms has partnered with leading clinic Releaf to bring cannabis containing meaningful levels of THCV (Tetrahydrocannabivarin), a cannabinoid linked to reduced appetite in emerging research, to patients in the UK for the first time since 1973.
As new national guidance instructs officers to treat medical cannabis users as patients first, James Duckenfield, CEO of Glass Pharms, reflects on what training police forces has taught him about the gap between the law and the general understanding of the legal landscape, and how the industry as a whole can help close it.
Under the collaboration, Glass Pharms will supply high-quality cannabis flower for use in Mamedica-branded, clinician-prescribed products, reinforcing the value of a fully domestic supply chain for CBPMs (Cannabis-Based Products for Medicinal Use).
